Inovio announced (July 23 / 2014) HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial. The price per share closed today @ $12.63, that's 11% lower than the post-announcement high of $14.20 and 20% lower than the 52 week high of $15.80. As the market digests this HUGE news and we await "detailed study findings will be submitted for publication in a peer-reviewed scientific journal", I would expect to see some extreme volatility to continue. I have a long position ACB $8.20 and I actively swing-trade as opportunities arise. Pull-back(s) such as where we are now are the opportunities I seek. I expect to see many upgrades in the near future and the possibility(s) of partnerships could be announced anytime. As with any small-cap bio stock, dilution is a possibility in order to fund ongoing phase 1 & 2 clinical trials or future phase 3 trials. **Note** I am particularly interested in the possibility of a gap (getting filled) that formed on the daily chart on July 23rd (phase 2 data released) @ $11.60 - $12.00. Hope you enjoy the chart and have great trades in the future.
Comments
snoooop40
⋅
Correction on the date of The Street Article. It was actually posted on June 10th 2014. The fall in price during Mar & Apr is most likely associated with the announcement of the reverse stock split.